NEW YORK ─ Digital pathology firm Proscia said on Tuesday that it has established a strategic partnership with European diagnostic services firm Unilabs to accelerate the adoption of artificial intelligence in routine pathology practice.
Through the collaboration, Unilabs will validate the efficacy of Proscia’s computational pathology applications and deploy them into its high-throughput pathology workflows, Proscia said.
Financial and other terms of the agreement were not disclosed.
Geneva-based Unilabs will implement computational pathology methods into its routine workflows leveraging Proscia’s suite of AI applications, and initially use the digital pathology firm's DermAI product, which classifies images of skin biopsies, Proscia said. Unilabs will test the utility of Proscia’s computational applications and generate clinical and economic evidence that reflects their capacity to achieve their intended purposes.
Philadelphia-based Proscia added that it will also collaborate with Unilabs to create de-identified datasets, while adhering to data protection regulations.
"The adoption of AI is poised to make the biggest impact on pathology since the introduction of light microscopy over a century ago," Claudio Silvestrin, head of the AI Centre of Excellence at Unilabs, said in a statement.
Earlier this month, Proscia and Ibex Medical Analytics said that they have agreed to combine their technologies into an integrated product for AI-based prostate cancer diagnosis.